SCHEMBL6164400

SCHEMBL6164400

O=c1[nH]c2ccc([S+]([O-])CCN3CCC(Cc4cccc(F)c4F)CC3)cc2o1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 6/20 0.47
GRIN2B Q13224 6/20 0.47
GRIN2D O15399 4/20 0.47
GRIN3B O60391 4/20 0.47
GRIN2A Q12879 4/20 0.47
GRIN2C Q14957 4/20 0.47
GRIN3A Q8TCU5 4/20 0.47
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
KDM1A O60341 1/20 0.36
TSHR P16473 1/20 0.36
DRD2 P14416 3/20 0.35
HTR2A P28223 2/20 0.35
HTR1A P08908 1/20 0.35
SLC6A4 P31645 1/20 0.35
HRH1 P35367 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6164799 0.93 GRIN2B (0.48) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6161400 0.90 GRIN1 (0.49) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6160890 0.87 GRIN1 (0.51) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
Besonprodil SCHEMBL2257896 0.84 GRIN1 (0.66) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
Besonprodil SCHEMBL29388542 0.84 GRIN1 (0.66) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6163800 0.84 GRIN1 (0.62) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6169604 0.83 GRIN1 (0.43) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6163199 0.82 GRIN1 (0.44) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6162014 0.81 GRIN1 (0.54) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL6161788 0.80 GRIN1 (0.54) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1089735-B1 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 2005-06-08 EP claimed
US-20030004187-A1 Method for preventing dyskinesias WARNER-LAMBERT COMPANY LLC 2003-01-02 US claimed
EP-1254661-A1 Method for preventing dyskinesias with selective NMDA-Antagonists WARNER-LAMBERT COMPANY (US) 2002-11-06 EP claimed
US-6284774-B1 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS WARNER-LAMBERT COMPANY 2001-09-04 US claimed
EP-1089735-B1 4-BENZYL PIPERIDINE ALKYLSULFOXIDE HETEROCYCLES AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS WARNER LAMBERT CO (US) 2005-06-08 EP disclosed
US-20030004187-A1 Method for preventing dyskinesias WARNER-LAMBERT COMPANY LLC 2003-01-02 US disclosed
EP-1254661-A1 Method for preventing dyskinesias with selective NMDA-Antagonists WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
US-6284774-B1 NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS WARNER-LAMBERT COMPANY 2001-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004187-A1 Method for preventing dyskinesias GRIN2B, GRIN2A, GRIN3A GRIN1 4/4885GRIN2B 1/4885GRIN2D 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.